×
Newsmax TV & Webwww.newsmax.comFREE - In Google Play
VIEW
×
Newsmax TV & Webwww.newsmax.comFREE - On the App Store
VIEW
Skip to main content
Tags: Coronavirus | Financial Markets | Health Topics | Infrastructure | Money | Vaccines | FDA

FDA Authorizes AstraZeneca's COVID-19 Antibody Drug

AstraZeneca
(AP)

Wednesday, 08 December 2021 04:08 PM

U.S. drug regulator Food and Drug Administration (FDA) said Wednesday it had authorized AstraZeneca's antibody cocktail to prevent COVID-19 infections in individuals who have weak immune systems or a history of severe side effects from coronavirus vaccines.

While vaccines rely on an intact immune system to develop targeted antibodies and infection-fighting cells, AstraZeneca's therapy Evusheld contains lab-made antibodies designed to linger in the body for months to contain the virus in case of an infection.

"Vaccines have proven to be the best defense available against COVID-19," said Patrizia Cavazzoni, director of the FDA's Center for Drug Evaluation and Research.

Pre-exposure prevention with Evusheld is not a substitute for vaccination in individuals for whom COVID-19 vaccination is recommended, the FDA said.

© 2022 Thomson/Reuters. All rights reserved.


StreetTalk
U.S. drug regulator Food and Drug Administration (FDA) said Wednesday it had authorized AstraZeneca's antibody cocktail to prevent COVID-19 infections in individuals who have weak immune systems or a history of severe side effects from coronavirus vaccines.
FDA, AstraZeneca, COVID-19 antibody drug
120
2021-08-08
Wednesday, 08 December 2021 04:08 PM
Newsmax Media, Inc.
Join the Newsmax Community
Read and Post Comments
Please review Community Guidelines before posting a comment.
 
TOP

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

NEWSMAX.COM
America's News Page
© Newsmax Media, Inc.
All Rights Reserved
Download the NewsmaxTV App
NEWSMAX.COM
America's News Page
© Newsmax Media, Inc.
All Rights Reserved